Is Dayvigo (Lemborexant) Safe During Pregnancy? What Women Need to Know

The Short Answer: Lemborexant Is Not Recommended During Pregnancy

Lemborexant should not be used during pregnancy. The FDA-approved prescribing information for Dayvigo states that there are no adequate and well-controlled studies in pregnant women, and animal reproductive toxicity data raise enough concern that the label advises caution and discusses risks with patients who are pregnant or planning pregnancy. No dose has been established as safe in human gestation.

This matters because insomnia is genuinely common in pregnancy. Up to 78% of pregnant women report significant sleep disturbance, and many arrive at pregnancy already using a prescription sleep aid. If you are one of them, this article gives you the evidence, the alternatives, and the practical next steps.

What Is Lemborexant and How Does It Work?

Lemborexant belongs to a class called dual orexin receptor antagonists (DORAs). Rather than globally sedating the central nervous system the way benzodiazepines or z-drugs (zolpidem, eszopiclone) do, DORAs block orexin-A and orexin-B from binding their receptors in the hypothalamus and brainstem, quieting the brain's arousal circuits while largely leaving other systems alone.

Why the Mechanism Matters for Pregnancy

Orexin neuropeptides do more than regulate sleep. The orexin system is active in placental tissue and the fetal brain, and animal research suggests it may play a role in fetal breathing movements and autonomic development. Blocking orexin signaling at a time when fetal neural circuits are forming is the core biological reason why caution is warranted, even before you look at the reproductive toxicology data.

The SUNRISE Trials: What the Key Efficacy Studies Did Not Include

The phase 3 SUNRISE-1 and SUNRISE-2 trials that led to FDA approval in 2019 enrolled adults with insomnia disorder and excluded pregnant and breastfeeding women. SUNRISE-1 demonstrated that lemborexant 5 mg and 10 mg significantly reduced sleep onset latency versus placebo and versus zolpidem extended-release, but no reproductive safety data were generated in these trials. The evidence base for pregnancy simply does not exist from the clinical trial program.

Human Pregnancy Data: The Honest Picture

No published, peer-reviewed controlled study has evaluated lemborexant exposure during human pregnancy and measured fetal or neonatal outcomes. This is not unusual for a drug approved in 2019; post-marketing pregnancy surveillance takes years to accumulate.

The FDA label instructs healthcare providers and patients to report pregnancies that occur during lemborexant treatment to the Dayvigo pregnancy exposure registry. As of this writing, no registry results have been published in the peer-reviewed literature.

What "No Human Data" Actually Means for You

Absence of data is not the same as evidence of safety. When human data are absent:

• Clinicians cannot reassure you that first-trimester exposure is harmless.
• They also cannot calculate an absolute risk increase, because the denominator is unknown.
• Risk assessment falls back on animal studies and pharmacological reasoning, both of which are imperfect proxies for human fetal risk.

This is an evidence gap that must be named honestly. Women have historically been excluded from clinical trials, and sleep-disorder drug development is no exception. The orexin antagonist class as a whole has limited reproductive safety data in humans, and lemborexant has even less than suvorexant (Belsomra), which was approved four years earlier.

Animal Reproductive Toxicology: What the Studies Found

The FDA prescribing information for Dayvigo summarizes nonclinical reproductive toxicology studies conducted in rats and rabbits. These are the only controlled safety data available for this drug in any gestational context.

Rat Embryo-Fetal Development Studies

In rat studies, lemborexant administered during organogenesis at doses producing plasma exposures approximately 16 times the maximum recommended human dose (MRHD) of 10 mg resulted in increases in fetal skeletal variations. At exposures approximately 32 times the MRHD, fetal body weights were reduced. No external malformations were observed at these dose levels in rats.

Rabbit Embryo-Fetal Development Studies

Rabbit studies showed no increase in malformations at exposures up to approximately 2 times the MRHD. However, the rabbit study achieved lower plasma multiples than the rat study, which limits the power of the negative finding.

Peri- and Postnatal Studies

In rat peri- and postnatal studies, maternal doses producing exposures approximately 16 times the MRHD resulted in decreased pup body weight and effects on offspring neurobehavioral development. These findings raise particular concern because the orexin system is involved in arousal and autonomic regulation in the developing neonate.

Putting the Animal Data in Context

Animal-to-human extrapolation is imperfect. Doses that cause harm in rats at 16 times the human exposure may or may not predict harm at therapeutic human doses. However, standard FDA and ACOG guidance on medication use in pregnancy holds that when animal studies show fetal harm and human data are absent, prescribers should avoid the drug in pregnancy unless the maternal benefit clearly outweighs the unknown fetal risk. For insomnia, where non-pharmacological alternatives exist, that threshold is rarely met.

Pregnancy/Lactation/Contraception: The Required Clinical Section

Pregnancy: Recommendation and What to Do If You Are Already Taking Dayvigo

Stop before trying to conceive. If you are planning a pregnancy, discuss transitioning off lemborexant with your prescriber before you start trying. There is no established washout period specifically required in the label, but given the drug's elimination half-life of approximately 17 to 19 hours, it clears the body within five to six days under normal conditions.

If you became pregnant while taking Dayvigo, do not abruptly stop without speaking to your clinician first (abrupt discontinuation of any sleep aid can cause rebound insomnia). Report the exposure to the Dayvigo pregnancy registry and to your OB. Your provider will likely transition you to a non-pharmacological approach or, if medication is genuinely necessary, to an agent with better-characterized human pregnancy data.

Teratogen framing: Lemborexant is not classified as a proven human teratogen. That distinction matters. A single first-trimester exposure before a woman knew she was pregnant does not automatically mean fetal harm. It means the risk is unknown, and close monitoring is reasonable.

Lactation: What Is Known (Almost Nothing) and Why It Matters

No human lactation data for lemborexant exist in LactMed or the published literature. It is unknown whether lemborexant or its metabolites transfer into human breast milk. Animal lactation data are also absent from the publicly available label summary.

Two concerns compound the data gap:

1. Transfer risk. Lemborexant is lipophilic and moderately protein-bound (approximately 94%). Lipophilic drugs can concentrate in breast milk. Without measured milk-to-plasma ratios, the infant dose cannot be estimated.
2. Galactagogue interference. Orexins appear to modulate prolactin release. Blocking orexin receptors pharmacologically may theoretically suppress lactation or reduce milk supply, though this has not been studied directly in nursing women.

The FDA label states that breastfeeding is not recommended during lemborexant treatment. If postpartum insomnia is severe enough to require medication, short-term low-dose doxylamine (which has more lactation data) or referral for CBT-I are preferable options to discuss with your provider.

Contraception Requirement

Women of reproductive potential who take lemborexant should use reliable contraception. The animal reproductive toxicity data constitute the basis for this recommendation. A positive pregnancy test while on the drug should prompt immediate contact with your prescriber and OB, followed by registration in the pregnancy exposure registry via the Dayvigo prescribing information contact line.

How Insomnia Changes Across Female Life Stages

Sleep disruption is not evenly distributed across a woman's reproductive life, and that unevenness shapes how you weigh the risk of any sleep medication.

Trying to Conceive (TTC)

Sleep quality affects hypothalamic-pituitary-ovarian axis function. Severe sleep disruption can suppress LH surge timing and reduce fertility. The temptation to manage TTC-related anxiety-driven insomnia with medication is real. Lemborexant should be stopped before active conception attempts. CBT-I delivered via app or telehealth is the preferred approach.

First Trimester

Nausea, breast tenderness, frequent urination, and anxiety drive sleep disruption starting in weeks six to eight. This is also the period of highest teratogenic vulnerability (organogenesis). Any sleep medication started or continued through the first trimester carries the most developmental risk. ACOG recommends CBT-I as the first-line treatment for insomnia in pregnancy at all trimesters, with medication reserved for refractory cases after a risk-benefit discussion.

Second and Third Trimesters

Physical discomfort, restless legs syndrome (which affects up to 26% of pregnant women), and fetal movement disrupt sleep as pregnancy progresses. If medication becomes unavoidable, agents with longer safety records in human pregnancy (such as low-dose doxylamine with pyridoxine, used for nausea and with some sleep data, or short-term low-dose diphenhydramine discussed with a provider) are preferred over a DORA with no human gestational data.

Postpartum and Lactation

Postpartum insomnia is often conditioned rather than purely physiological, meaning CBT-I works particularly well. For women who are breastfeeding, lemborexant is not recommended. For women who are formula feeding and experiencing severe postpartum insomnia that is not responding to behavioral approaches, a prescriber may consider the risk-benefit individually, though published data remain absent.

Perimenopause and Post-Menopause

Lemborexant is FDA-approved for insomnia in adults without a gestational age restriction, and the SUNRISE program included perimenopausal and postmenopausal women. The drug has a reasonable evidence base for this life stage and pregnancy is not a concern. This is where the risk-benefit calculation shifts most clearly in the drug's favor.

Who This Is Right For. Who It Is Not Right For.

The following framework helps organize the clinical decision across life stages.

Lemborexant May Be Appropriate For

• Non-pregnant, non-breastfeeding adults with chronic insomnia disorder who have not responded to CBT-I
• Postmenopausal women with insomnia who have contraindications to hormonal sleep support
• Women with comorbid conditions where CNS-depressant sedatives (benzodiazepines, z-drugs) carry higher risk (fall risk, substance use history), since DORAs have a different safety profile in these populations
• Women with PCOS who have insomnia and are not pregnant or TTC, given that sleep disruption worsens insulin resistance in PCOS and treating insomnia effectively matters

Lemborexant Is Not Appropriate For

• Pregnant women at any trimester
• Women actively trying to conceive (discontinue before TTC)
• Breastfeeding women
• Women who are not using reliable contraception

Safer Alternatives for Insomnia During Pregnancy

Non-pharmacological treatment is not a fallback. CBT-I achieves remission in 50 to 60% of patients with chronic insomnia and carries no fetal risk. It is the first-line recommendation from ACOG, the American Academy of Sleep Medicine, and the American College of Physicians.

CBT-I: The Evidence-Based First Line

CBT-I components that work in pregnancy include sleep restriction therapy (abbreviated for pregnant women), stimulus control, cognitive restructuring of catastrophic sleep beliefs, and relaxation training. Digital CBT-I programs (Sleepio, Somryst) have been validated in general adult populations and can be delivered without in-person appointments.

Pharmacological Options When CBT-I Is Insufficient

| Agent | Human Pregnancy Data | Lactation Data | Key Caveat | |---|---|---|---| | Doxylamine 10 mg plus pyridoxine 10 mg (Diclegis/Bonjesta) | Extensive; used for nausea/vomiting of pregnancy | Limited; use with caution | Licensed for nausea; off-label for sleep | | Diphenhydramine 25 mg | Large observational exposure data; generally reassuring | Transfers to milk; may suppress lactation | Third trimester use associated with neonatal withdrawal reports | | Zolpidem | More human data than lemborexant; neonatal sedation risk; preterm birth signal in some studies | Transfers to milk | Not preferred but better characterized than lemborexant | | Melatonin low dose | Limited controlled data; generally low risk profile biologically | Unknown milk transfer | Not FDA-approved for insomnia; OTC use is common |

Always discuss these options with your OB or maternal-fetal medicine specialist before starting anything during pregnancy. The table above is a clinical framework, not a prescription.

What to Do If You Took Lemborexant Before Knowing You Were Pregnant

First: a single or short-duration exposure to lemborexant before you realized you were pregnant does not mean your pregnancy is high-risk. The animal data show harm at doses 16 to 32 times the human therapeutic exposure, not at therapeutic doses. The risk to your specific pregnancy from brief early exposure is genuinely unknown, which is different from "definitely harmful."

Steps to take:

1. Contact your OB or midwife and tell them the drug, dose, and dates of exposure.
2. Ask your prescriber to enroll you in the Dayvigo pregnancy exposure registry (information in the FDA-approved prescribing information).
3. Standard first-trimester screening (nuchal translucency ultrasound, cell-free DNA or quad screen) should proceed on its normal schedule.
4. A second-trimester anatomy ultrasound at 18 to 20 weeks is standard of care and will assess fetal structure in detail.
5. Transition to CBT-I or another evidence-based non-pharmacological approach for the remainder of the pregnancy.

Maternal anxiety about medication exposure is itself a sleep disruptor and a stressor. Getting factual information and a clear plan from your OB team is the most productive next step.

Pharmacokinetic Considerations Specific to Pregnancy

Pregnancy changes how nearly every drug behaves in your body. Plasma volume expands by 40 to 50%, renal clearance increases, and hepatic enzyme activity shifts depending on the trimester. CYP3A4, the main enzyme responsible for lemborexant metabolism, is induced during pregnancy, meaning drug levels may be lower than in non-pregnant adults at the same dose. Lower maternal plasma levels could reduce fetal exposure, but placental transfer of lemborexant has not been measured, so this is speculative. These pharmacokinetic shifts reinforce why pregnant-specific dosing data are necessary before any drug is considered safe in gestation.

A Note on the Evidence Gap for Women

Lemborexant is a post-2014 drug, approved under the FDA Pregnancy and Lactation Labeling Rule (PLLR) that replaced the old A/B/C/D/X letter categories. Under PLLR, the label must describe the actual data rather than assign a letter grade. For lemborexant, that description is essentially: human data absent, animal data concerning at supratherapeutic doses, registry in progress.

Women of childbearing age make up a substantial portion of people with chronic insomnia. Insomnia disorder is approximately 1.4 times more common in women than men, yet the reproductive safety program for lemborexant generated no human gestational data before or after approval. That gap is a systemic problem in drug development that the pregnancy exposure registry is meant to address over time. Until registry data accumulate and are published, clinicians and patients are working with incomplete information. Naming that limitation is not alarmist; it is the accurate clinical picture.